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Disorder (IMD)
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?????????????????????????????????????????????????
start.
???????????????????????????????????????????
hands! This time it is a ‘Rare Edition’ in line with 
the Rare Disease Day celebrated worldwide on the 
last day of February every year. The Department 
of Pathology and Laboratory Medicine has been 
celebrating World Rare Disease Day since 2015 with 
the objectives of raising awareness and educating 
physicians and pathologists regarding few of the 
rare diseases. Diagnosis and management of rare 
diseases in Pakistan has been challenging due to 
resource constraints, limited expertise and rarity of 
cases. Although individually rare, some disorders are 
collectively common in Pakistan. Due to the lack of 
diagnostic facilities and absence of national registries 
for most of these diseases, the exact prevalence of 
various rare diseases are not known. Diagnosis and 
management of rare diseases is a challenge and 
that’s why team of LabRad this time is committed in 
disseminating information and knowledge on various 
rare diseases to our readers. This issue focuses 
on rare diseases like inherited disorders, certain 
dermatopathologies, bone diseases and infections.
Just to remind you all, since last few years LabRad is 
marked in the Institutional Repository and available 
on http://ecommons.aku.edu/pakistan . Readers from 
outside Aga Khan University now have the access 
current and previous issues of LABRAD from here 
and this has improved our newsletter readership.
I hope you enjoy this issue.  
Happy reading.
Lena
From the Editor’s Desk
Evaluation of Amino Acidopathies and 
Organic Acidurias
Dr Lena Jafri
Clinical Chemistry
Overview: Amino acidopathies (AA) and organic 
acidurias (OA) are single gene inherited metabolic 
disorders (IMDs) due to absolute or relative 
?????????????????????????????????????????????
may be considered in three broad categories: 
disorders of acute or progressive intoxication or 
encephalopathy; disorders associated with energy 
????????????????????????????????????????????
????????????????????? ????????????????????????????
signs and symptoms are caused by accumulation 
of toxic compounds proximal to the metabolic 
block and in the second type signs and symptoms 
????????????????????????????????????????????????????
???????????????????????????????????????? ???????????
skeletal muscle, or brain. The third category includes 
peroxisomal and lysosomal storage disorders. 
???????????????????????????????????????????
?????? ?????????????????????????????????????????
risk factors for IMD like parental consanguinity, 
history of unexplained neonatal or sudden infant 
disease in siblings or maternal male relatives. 
These disorders can be triggered or precipitated by 
certain triggers which may include the introduction 
of complementary foods (e.g. infant cereals, fruit 
juices, and pureed fruits, vegetables) to the infant 
diet. Infection, fever, or fasting can also precipitate 
the underlying disorder like urea cycle defects, 
amino acid disorders, organic acidemias, fatty acid 
oxidation disorders, etc. IMD may be detected by 
any of the two ways:
?? Detection through universal newborn screening  
 in asymptomatic babies. 
? Presentation clinically with symptoms and 
 signs. These patient are occasionally very sick 
? ???? ??????????????????? ????????????? ?????????
 if the diagnosis and appropriate management are 
 delayed.
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 of amino acids in plasma, urine and CSF, 
 urinary organic acids and urinary 
 succinylacetone. Previously, the same samples 
 would have to be sent abroad for selective 
 screening and diagnosis of IMD. Since 2013 
 the clinical laboratory has been providing the 
 facilities for testing for IMD in the country 
? ?????????????????????????????? ?????????????????
 disease and homocytinuria have also been 
? ??????????????????????????????????????????????????
 AA and OA demands extensive laboratory 
 support including skills in analysis and 
 interpretation of chromatograms and close liaison 
 with clinicians and correlation with clinical 
 history. 
?? ??????????????????????????????????????????
? ?????????????????????????????????????????????
? ?????????????????????????????????????? ????????
 based analysis can be done. Although 
? ???????????????????????????????????????????????
? ?????????????????????????????????????????
 and/or molecular testing after suggestive 
 biochemical diagnosis, will help in prenatal 
 genetic counselling and prenatal genetic 
 diagnosis for the couple at risk. Carrier screening 
 for at risk family members followed by genetic 
 counselling for couples and pre-marital genetic 
 counselling for carrier to make informed 
 decisions to choose their partners can contribute 
 in reducing the overall burden of IMD in 
 Pakistan.
Burden of AA and OA as evident from our 
laboratory data:  Patients with signs and symptoms 
suggestive of IMD (n=12161) were investigated 
in our Biochemical Genetics Laboratory from 
2013-2017 by analysis of urinary organic acids, 
succinylacetone and plasma amino acids. IMDs 
were detected in 546 cases (4.5 percent). Organic 
acidurias were most common (57 percent) followed 
by aminoacidopathies (29 percent) and other IMDs 
(14 percent). Common organic acidurias were: 
With no national newborn screening program 
??????????????????????????????????????????????????????
in newborns. The Biochemical Genetics Laboratory 
at the Section of Clinical Chemistry, Department of 
Pathology and Laboratory Medicine AKUH mostly 
receives samples from symptomatic children with 
clinical manifestations varying from acute life 
threatening disease to developmental delays and 
progressive degenerative disorders. 
Laboratory Approach to AA and OA: Critical 
metabolic thinking is occasionally the vehicle for 
the accurate diagnosis. In order to reach a precise 
diagnosis, a thorough history, a comprehensive 
physical examination and rational plan of 
investigation (Table 1) should be in place. Following 
approach is essential for evaluation of IMD in a 
child/adult:
?? Comprehensive Clinical History: This should 
 include signs and symptoms, physical 
 examination (eg dermatitis, alopecia, facial 
? ????????????????????????????????????????????
 antenatal and birth history, drug history, 
 nutritional history, family history, available 
 radiological and laboratory investigations 
 and any provisional diagnosis. Sick looking 
 baby may suggest intoxication especially in 
 presence of stigmata of encephalopathy such as 
? ????????????????????????????????????????????
 Section of Clinical Chemistry has developed 
? ??????????????????????????????????????????????
 by clinicians prior to sending samples for second 
 tier tests (described ahead in this article).
? First tier tests: These include complete blood 
 count, Urine detailed report, plasma glucose, 
 plasma ammonia, plasma lactic acid, arterial 
 blood gases, liver and kidney function tests and 
 electrolytes. Table 2 shows 
? Second tier tests: The test is performed on the 
 basis of clinical context and includes quantitation 
First Tier Tests
? CBC, 
? Urine D/R 
? Blood Glucose
? Plasma Ammonia 
? Plasma Lactic Acid 
? Arterial Blood Gases
? Electrolytes
Second Tier Tests
?? ??????????????????????????????????
 of Amino Acids
? Urine Organic acids
? Urine Succinylacetone
???????????????????????????????????????
?? ????????????
?? ????????????????????? ????????????????
Table 1: First tier tests and specialized tests available for IMD testing at the Clinical Laboratory of AKUH
???????????????????????????????????? ?????????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????
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methylmalonic aciduria (33.9 percent), multiple 
??????????????????????????????????????????????????
aciduria type 1 (7.7 percent). Frequent amino 
acidopathies were maple syrup urine disease (28.3 
percent), hyperphenylalaninemia (27 percent) and 
urea cycle disorders (17.6 percent). This data is 
valuable and endorses that although individually rare, 
IMDs are collectively common in Pakistan. With no 
national newborn screening program and high rate 
of consanguineous marriage rate this is just the tip of 
the iceberg and the exact burden of IMDs is expected 
to be high.
??????????????????????? ?????????????
?????????? ???????????????????????
????????????????????????????????????????????
recessively inherited disorder in which an individual 
with the disorder is unable to recycle biotin. Biotin 
is required as a cofactor for optimal activity of four 
carboxylases that are involved in the gluconeogenesis 
(pyruvate CoA carboxylase), the initial step of fatty 
acid synthesis (acetyl CoA carboxylase), and the 
catabolism of several branched-chain amino acids 
????????????????????????????????????????????????
CoA carboxylase). Biotin is normally required in 
a very small quantity as most of it is recycled by 
????????????????????????????????????????????????????
from the organic compound, biocytin. Biotin is 
recycled in the body when BTD liberates biotin from 
endogenous and dietary proteins, shown in Figure 1. 
????????????????????????????????????????????????
recycling, in turn leading to declining carboxylase 
???????????????????????????????????????????? ?????????
function. 
Clinical and Diagnostic features of BTD 
?????????
???????????????????????????????? ????????????????
?????????????????????????????????????????????????
and vision loss, ataxia, skin rash and alopecia. If 
?????????????????????????????????????????????????
development and eventually mental retardation.  
With the introduction of urine organic acid analysis 
at the clinical laboratory of Aga Khan University in 
Ms Maria Masood
Clinical Chemistry
??????????????????????????????????????????????????????????????????????????????????????
Findings
Metabolic Acidosis
Respiratory Alkalosis
Hyperammonemia
Hypoglycemia
Ketones
Lactic Acidosis
MSUD
±
-
±
±
A/ H
±
OA
++
-
+
±
H
±
UCD
-
+
++
-
A
-
DCM
±
-
-
+
A/ H
+
FAO
±
-
±
+
A/ L
±
Abbreviations used:
MSUD: Maple syrup urine disease; OA: Organic acidemia; UCD: Urea cycle disorders; 
DCM: Disorders of carbohydrate metabolism; FAO:   Fatty acid oxidation
Symbols used:
-  usually absent
±  sometimes present
+  usually present
++  always present
A  appropriate
H  inappropriately high
L  inappropriately low
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????????????????????? ?????????????????????????????????
??????????????????
???????????????????????????????????????????????????
???????????????????????????????????????????????????
have been noted. 
?????????????????????????????????????????
?????????????????????????????????????????????????
?? ???????????????????????????????????????
 activity of <10 percent. Biochemically, these 
 patients present with metabolic abnormalities 
 such as; ketolactic acidosis, organic aciduria, and 
 /or  mild hyperammonemia.
?? ???????????????????????????
 milder form of this condition 
? ??????????????????????????
 activity. On organic acid analysis,  
 increased excretion of 
 3-hydroxyisovaleric acid may   
? ???????????????????????????????
 which may appear only during 
 illness, infection, or other times 
 of stress.
?????????????????????????????????????
by lifelong biotin therapy. However, 
it is important to consistently monitor 
??????????????????????????????????????
the dose of biotin should be increased. 
This is best accomplished by periodic assessment 
of organic acids in urine, especially if the individual 
develops symptoms and is compliant with treatment. 
Due to the salvageable nature of this IMD, it is now 
included in newborn screening panels in most of the 
countries.
Identifying Alkaptonuria by Urinary Organic 
Acid Analysis
Dr Aysha Habib Khan
Clinical Chemistry
Alkaptonuria is a rare genetic disorder in the 
?????????????????????????????? ????????????????????
by Sir Archibald Garrod in 1902. The true frequency 
is not known and wide variability in incidence 
is reported. The underlying pathophysiology is 
?????????????????????????????????????????????????????
homogentisate 1, 2-dioxygenase (HGO), Figure 1. 
This results in accumulation of homogentisic acid 
(HGA) in the tissues giving rise to onchronosis. 
There is bluish black discoloration of connective and 
other tissues especially cartilage, tendons, ligaments 
and even bone within the body. Discoloration and 
irregularity of cartilage within the ear is usually 
???????????????????????????????????????????????
discolored, brittle and weak and susceptible to 
rupture. Eventually discoloration of tendons may 
become visible on the overlaying skin. 
???????????????????????????????????????????????????
??????????????????????????????? ????????????????
accumulation of HGA. Long standing alkaptonuria 
????????????????????????????????????????????
(arthritis) especially in the spine and large joints 
(ochronote arthropathy). Arthritis can be severe and 
?????????????????????????????????????????????????
symptoms and are sometimes seen before the age 
of 30. Joint disease begin earlier and progress more 
rapidly in males than females. Additional symptoms 
Free Biotin
Biotin Transport
Lysine
Biotinylation of
histones, etc. ?
Blocytin
Free Biotin Pool
Holocarboxylases
PCC. MCC. PC. ACC
Proteolysis of dietary biotin-bound
and other biotinylated proteins
Amino Acid Catabolism, Fatty Acid Synthesis and Gluconeogenesis
THE BIOTIN 
CYCLE
Holocarboxylases
Synthetase
Biotinidase
Apocarboxylases
PCC. MCC. PC. ACC
ATP
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are seen less often include kidney stones in 50 
?????????????????????????????????????????????????
age. Prostate stones have also been described in 
men. In some individuals, heart disease develops 
due to accumulation of HGA within the aortic or 
mitral valve. Joint and spinal symptoms associated 
can resemble symptoms associated with other 
disorders such as RA, ankylosing spondylitis and 
osteoarthritis.
Blackening of urine when left standing for 24 hours 
is an important clue to diagnosis. Dark staining of 
diapers indicate the presence of disease in infants 
(also known as black diaper disease) but only 21 
percent of patients are diagnosed before 1 year of 
age. Other simple urinary studies include darkening 
of urine on standing with the addition of sodium 
hydroxide, black reaction with FeCl3.
HGA is excreted in the urine and detected in urine 
by gas chromatography mass spectrometry (GC-
MS) analysis. Since the time of introduction of 
GC-MS technique in our Clinical Laboratory; 
??????????????????????????????????? ?????????????
Alkaptonuria is frequently an under-diagnosed 
disease. Late presentation and diagnosis is the 
hallmark of cases presented in Pakistan. The most 
?????????????????????????????????????????????????
decade of life. Patients usually has musculoskeletal 
symptoms not considered to have alkaptonuria. 
However, case reporting by physicians all across 
Pakistan has raise some awareness among the general 
population and general practioners. However, much 
still needs to be done regarding its awareness so that 
early diagnosis could lead to better management and 
??????????????????????????????????
?????????????? ????????????????????????????? ??????????
Fumarate Acetoacetate
Phenylalanine
Hydroxylase
Tyrosine
Aminotransferase
homogentisate 1,
2-dioxygenase
Fumarylacetoacetate
4-Hydroxyphenylpyruvate
Dioxygenase Homogentisate
(Appear in Urine)
benzoquinone
acetic acid
(deposits in tissues)
Polyphenol
Oxidase
Phenylalanine
Tyrosine
4-Hydroxyphenylpyruvate
Homogentisate
Maleylacetoacetate
Fumarylacetoacetate
Utility of Urine Succinylacetone in Diagnosing 
Tyrosinemia Type I
Dr Syed Bilal Hashmi and Mr Nasir Ali
Clinical Chemistry
Tyrosine is an aromatic amino acid important in the 
synthesis of thyroid hormones, catecholamines and 
melanin. Impaired catabolism of tyrosine is a feature 
of several acquired and genetic disorders that may 
result in elevated plasma tyrosine concentrations.
Tyrosinemia type I is an autosomal recessive 
?????????????????????????????????????????????
fumarylacetoacetate hydrolase (FAH), which 
is required to break down the amino acid 
tyrosine. Failure to properly break down 
tyrosine leads to abnormal accumulation of 
tyrosine and its metabolites; succinylacetone and 
succinylacetoacetate in the liver, resulting in severe 
liver disease. Tyrosine may also accumulate in the 
kidneys and central nervous system. Others types of 
tyrosinemia includes type II and III. 
The incidence of tyrosinemia type I is 1/100,000 
worldwide. The age of onset is early infancy. The 
patient may present with renal tubular dysfunction 
with hypophosphatemic rickets, poor feeding, 
vomiting, hepatosplenomegaly, clotting disorder 
from liver failure and porphyria-like neurological 
8VOL. 45, ISSUE 1FEBRUARY 2019
crisis or cardiomyopathy.  If the patient remain 
undiagnosed at neonatal screening they can present 
with growth retardation, bruising, hepatomegaly 
and cirrhosis. The chronic form consists of a mixed 
micronodular and macronodular cirrhosis. The risk 
of developing hepatocellular carcinoma is high in 
untreated survivors, occurring in as many as 37 
percent of untreated patients older than two years of 
age. If untreated, patients with Tyrosinemia type I 
????????????????????????????????????????????????? ???
die of acute liver failure before the second year after 
birth or from chronic liver failure or hepatocellular 
carcinoma before the end of the second decade.
The diagnosis of tyrosinemia is done by measuring 
the elevated levels of tyrosine often with methionine 
????????????????????????????????????????????????
and organic acid ‘succinylacetone’ in the urine. 
???????????????????????????????????????????????????
concentrations of Alpha-fetoprotein (AFP), tyrosine, 
and methionine and excrete tyrosyl compounds in 
the urine. Elevation of urinary succinylacetone is 
pathognomonic for Tyrosinemia Type 1. Testing for 
plasma amino acids and urinary succinylacetone 
are available at the Clinical Laboratory of AKUH. 
??????????????????????????????????????????????
????? ??????????????????????????????????????????
Molecular testing for disease-causing mutations is 
available through multiple laboratories, but treatment 
???????????????????????????? ?????????????????????
is available. For accurate quantitation of 
succinylacetone in urine at diagnosis for Tyrosinemia 
type 1 recommended as initial or concurrent test and 
to monitor individuals with Tyrosinemia type 1 who 
are on nitisinone therapy.  Once diagnosed, children 
with tyrosinemia are treated with a medication called 
nitisinone (previously called NTBC) (Figure 1). A 
diet low in tyrosine, phenylalanine, and methionine, 
and a special medical formula is often recommended. 
In the long term, individuals with liver damage or 
liver cancer may require a liver transplant. Treatment 
can prevent liver disease, kidney problems, and the 
neurological problems that can be associated with 
tyrosinemia. 
Special Instructions for Sample Collection and 
Transport for Urinary Succinylacetone
????????????? ???????????????????????????????????????
analysis. Succinylacetone is photosensitive therefore 
protection of urine from light is advised. It can easily 
be done by wrapping the container with dark plastic 
bag. Urine succinylacetone is reported in mmol/mol 
creatinine and is normally not detected in urine.
Tyrosine
4-OH phenylpyruvate
Point of 
action of
NTBC
Succinylacetoacetate
Succinylacetone
Block in
Tyrosinemia 1
Fumarylacetoacetate
hydrolase
AcetoacetateFumarate
4-OH phenylpyruvate
dioxygenase
Maleylacetoacetate
Homogentisate
Fumarylacetoacetate
Figure 1: Pathway for degradation of tyrosine showing the defect in 
Tyrosinemia type 1 and the point of action of NTBC
RARE FACT
???????????????????????????
of Rare Diseases In the EU, 
?????????????????????????????
??????????
???????????????????????????
??????????????????????????
RARE FACT
?????????????????????
????????????????????? ??????
?????????????
??????????? ??????????????
??????????????????
??? ?????????????????????
??? ????????????????????????????
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Cardiac Manifestation of Inherited Metabolic 
Disorders
Dr Aysha Habib Khan
Clinical Chemistry
Cardiac involvement is a part of many inherited 
metabolic disorders (IMD). As the heart is a 
metabolically active organ, it can be adversely 
????????????????????????????????????????????????????
of cardiac involvement varies from 15 percent 
to 60 percent. While 5 percent of all causes of 
cardiomyopathy and 15 percent with known causes 
are due to IMDs. Cardiac manifestations among 
these patients include hypertrophic (HCM), dilated 
(DCM), and restrictive (RCM) cardiomyopathy, 
heart rhythm disorders, valvular defects, and 
congenital heart structure disorders. However, that 
more than one pattern of cardiac involvement may 
be present in some IMDs. 
Cardiomyopathy is the most frequent heart disorder 
in most IMDs and one of the major causes of 
?????????????????????????????????????????????????
during a multisystem evaluation of patients. IMDs 
accounted for 26.8 percent of known causes of 
hypertrophic cardiomyopathy, 6.8 percent of cases 
of dilated cardiomyopathy, 0percent of restrictive 
cardiomyopathy, and 26.9 percent of mixed/
other type of cardiomyopathy. Table 1 shows the 
???????????????????????????????????????????????
cardiomyopathy.
Heart rhythm disorders are mainly encountered 
in mitochondrial disorders and Acidaemias, 
whereas valvular dysfunction is a prominent 
?????????????????????????????????????????????????
in mitochondrial disorders, congenital disorders 
of glycosylation and acidemias usually constitute 
an early symptom. On the contrary, in storage 
disorders, heart problems are revealed in later 
stages during routine multisystem evaluation, with 
the exception of Pompe disease. 
In many cases, cardiac manifestations dominate 
the clinical phenotype, as they include one of 
the prominent symptoms. In other metabolic 
defects; however, heart problems consist of minor 
symptoms and are incidentally revealed during 
routine multisystem evaluation. Lastly, there are 
cases of metabolic errors in which the heart may be 
???????????????????????
?????????????????????????????????????????
???????????????????????????????????????????????
?????????????????????????????????????????????of 
Table 1: Inherited Metabolic Disorders That Cause Cardio?
myopathy
Disorders of Aminoacids & Organic Acid Metabolism
?? ??????? ???????????? ???????????????
• Malonic Acidemia
?? ????????????????????????????
• Mevalonic acidemia
• Tyrosinemia-HCM
• Oxalosis-HCM, RCM
Disorders of Fatty Acid Metabolism
• Carnitine Transporter Defects
• Fatty Acid Oxidation Disorders
• VLCAD-HCM
• SCAD-HCM, DCM
• MCAD-HCM
Disorders of Glycogen Metabolism
• GSD II –HCM
• GSD III-HCM
• GSD IX-HCM
?? ???????????????? ?????????????? ?????????????
• Danon Disease 
????????????? ???????????? ?????????????
Lysosomal Storage Disordres
• Disorders of Mucopolysacchride Metabolism
• MPS I, II, III, IV, VI, VII-HCM, DCM
• Disorders of Glycogen Metabolism
• GSD II- HCM
• Danon Disease-HCM
• Disorders of Glycosphinolipids Metabolism
• Gauchers Disease-HCM
• Fabry Disease –HCM
• Disorders of Combined Ganglioside, Mucopolysacchride 
 & Oligosacchride Metabolism
• GMI –HCM, DCM
• GMII-HCM, DCM
Mitochondrial Disorders
?? ????????????????????????????????????
• Complex I, II, III, IV, V-HCM, DCM
• MELAS-HCM
• MERF-HCM, DCM
• Barth Syndrome –HCM, DCM, Mixed
• Sengers syndrome-HCM
Peroximal Disorders
?? ??????????????????????
10
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• Family history suggestive of inheritance pattern
• Consanguinity
• A history of unexplained collapse or death within the   
 family/siblings
• Signs of heart failure
• Distinctive physical appearance
?? ??????????????????
?? ????????????????????????????????????????
• CCF often occurs in the setting of an acute metabolic 
 decompensation triggered by energy stressors, e.g., illness, 
 surgery, infection, fasting, or physical exertion. 
• Deterioration after a period of apparent normalcy
• Poor feeding, Poor weight gain in an infant or failure to 
 thrive
• Orthopnea or exercise tolerance in older child
?? ???????????????????????????????????????????????????
 unexplained cause
• Severe metabolic acidosis 
• Persistent vomiting
• Peculiar odor (urine, cerumen)
Table 2: High Index of Clinical Suspicion for IMD
???????????????????????????????????????????
???????????????????????????????????????????????????????
investigations. Chemical Pathologist has a great 
responsibility of appropriately diagnosing these 
conditions as over diagnosis or under diagnosis are 
both dangerous. A very close liaison is required 
between chemical pathologist and treating physician. 
Clinicians should provide related history of the 
patient to the Clinical Laboratory that helps in 
appropriate processing of the specimen and analysis; 
hence report interpretation and correct diagnosis.
cardiac myocytes with stored substrate and 
subsequent cellular damage, accumulation 
of intermediary metabolites, which exert a 
toxic effect on surrounding tissues and lead 
myocytes to apoptosis are the underlying 
pathophysiological basis of the diseases. In 
many cases more than one mechanisms may be 
involved, especially in later stages of the disease 
course. Identification of the underlying causes of 
cardiomyopathy may lead to improved outcome 
with disease-specific treatments. Knowing a 
specific diagnosis is important for accurate 
genetic counselling, family planning, prenatal 
diagnosis and the screening of younger and often 
presymptomatic siblings.
Diagnosis of IMDs is challenging due to episodic 
nature of metabolic illness, wide range of clinical 
symptoms that is also associated with more 
common conditions, low incidence of these 
disorders and consequent lack of experience 
among the pediatric sub-specialties on assessment 
of possible metabolic myopathy and what to do 
in clinical practice? Especially when to refer for 
metabolic screening? There is unfamiliarity with 
biochemical interrelationships/diagnostic tests and 
?????????????????????????????????????????????????????
Table 2 highlights the features that have high index 
of suspicion and should be investigated for probable 
IMD.
Hyperphenylalaninemia
Dr Sibtain Ahmed
Clinical Chemistry
Disorders of phenylalanine (Phe) metabolism are 
one of the most frequently presenting inherited 
metabolic disorders (IMDs). The prevalence of 
Hyperphenylalaninemia (HPA) is reported to be 
1:10,000. Date from Pakistan is scarce, however one 
study from our centre reported 34 cases over a period 
of four years.
From a historical perspective in 1934 – a Norwegian 
physician Absjørn Følling while examining two 
mentally retarded siblings, detected ‘phenylpyruvic 
acid’ on urine chemical analysis and proposed the 
term ‘imbecillitas phenylpyruvica’ which was further 
renamed by Lionel Penrose as ‘phenylketonuria’. 
In 1958 - Robert Guthrie developed a simple 
inexpensive screening test using dried blood spots 
?????????????????????????????????????????????????
Kaufman proposed that HPA are a heterogeneous 
group of autosomal recessive disorders which could 
????????????????????????????????????????????????????
hydroxylase (PAH) or defects in the metabolism 
or regeneration of its cofactor tetrahydrobiopterin 
????????????????????????????????????????????
triphosphate cyclohydrolase (GTPCH), 
6-pyruvoyl-tetrahydropterin synthase (PTPS), 
sepiapterin reductase (SR) and is regenerated by 
dihydropteridine reductase (DHPR) and pterin 
carbinolamine-4-dehydratase (PCD). Defect in BH4 
metabolism could be due to either GTPCH, PTPS, 
SR or its regeneration by DHPR and PCD. 
11
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umol/L in infancy and childhood result in near 
normal intellectual development. For each 300 
?????????????????????????????????????????????????
years of life IQ is reduced by 0.5 SD, and till 10 
years the corresponding reduction is 0.25 SD. 
Recommendations for monitoring treatment and 
outcome are shown in Table 02.
Patients with HPA must be diagnosed and treated 
before manifestation of clinical symptoms 
???????????????????????????????? ???????????????
???????????????? ??????????????????????????
is performed for the diagnosis of HPA, using 
3-4ml of blood samples collected in lithium 
heparin tube. Samples are transported in dry ice 
to the Biochemical Genetic Laboratory (BGL) 
after centrifugation from outreach phlebotomy 
centres. All samples are stored at -20°C prior to 
analysis. A questionnaire focusing on clinical and 
?????????????????????????????????????????????????????
and for patients whose samples are received at the 
?????????????????????? ???????????????????????
is performed by cation-exchange HPLC (Biochrom 
30+ model 440/570 nm), with a lithium column of 
4.6mm diameter. Standard, control and specimens 
are deproteinised with sulfosalicylic acid 10 percent 
and norleucine is added as internal standard. The 
results are analysed by EZ chrome software 3.31.
The reports of patients of PAA are reviewed in the 
departmental consultation conference comprising 
of a team of Consultant chemical pathologists and 
bench technologists and signed out by a Consultant 
chemical pathologist. PAA patterns consistent with 
liver disease are excluded and additionally Phe to 
Tyrosine ratio is also calculated, as a ratio of greater 
than three is considered consistent with HPA.
There is a dire need for local availability of 
pterin analysis and DHPR activity for easy access 
to physicians who can follow the appropriate 
diagnostic approach for patients with HPA and 
a comprehensive NBS program to identify such 
patients and attain better prognosis. 
In most of the developed countries having 
state mandatory new born screening (NBS) 
???????????????????????????????????????????????????
??????????????????????????????????????????
However, currently there is no NBS program in 
Pakistan and patients are often evaluated for IMD in 
clinical presentation of ‘metabolic crisis’ or ‘neuro-
regression’. Further evaluation of HPA occurring as a 
secondary consequence of a defect in the metabolism 
or regeneration of BH4 is done through analysis of 
urine or blood neopterin, biopterin and measurement 
of DHPR activity as shown in Figure 1 and Table 1. 
????????????????????????????????????????????????
in metabolism or regeneration of BH4 is important 
?????????????????????????????????????????????????????
better outcomes, carrier screening for high-risk 
family members, proper genetic counselling and 
future reproductive options for the carriers. Patients 
????????????????????????????????????????????????
On the contrary, for BH4 defects, Phe-restricted 
diet is often not needed but early supplementation 
with dopamine and serotonin precursors, and 
synthetic BH4 is required to attain symptomatic 
improvement.
Longitudinal studies have shown that dietary 
??????????????????????????????????????????????
of life with average blood Phe levels < 400 
New Born Screening
Plasma Amino Acid Analysis
Normal PheElevated Phe & Phe: Tyr ratio
Pterin proﬁle & DHPR activity
Normal Pterins Abnormal Pterins Reduced DHPR activity
Figure 01: Diagnostic Strategy for HPA
Table 01: Interpretation of Investigations
?????????
GTPCH
PTPS
DHPR
PCD
Blood or 
urine 
Biopterin
??
??
??
?
Blood or 
Urine 
Neopterin
??
??
N or??
?
Blood or 
Urine 
Primapterin
?
?
?
??
Blood 
DHPR 
activity
N
N
?
N
?????????? ??????????????????????????? ??????????????????
?????????? ???? ?????????????? ??????????????????????????
?????
Age
???????
???
???
???
?????
Adolescent/Adult
Blood Phe levels
Weekly
Fortnightly
Fortnightly
Monthly
?????????? ?????
Clinical Monitoring
Every 3 months
Every 3-6 months
Every 6 months
Every 6 months
Yearly
Monitoring
12
VOL. 45, ISSUE 1FEBRUARY 2019
Homocysteine (Hcy), a sulfur amino acid 
metabolism is an intermediate metabolite in 
methionine (Met) and folate cycle. Homocysteine 
is formed from Met via the numerous adenosyl-
methionine dependent methyl transfer reactions 
(Figure 1). Any imbalance between Hcy formation 
and removal will lead to changes in plasma 
tHcy concentrations. Homocysteine has primary 
atherogenic and prothrombotic properties, 
inducing vascular injury and lower Hcy levels are 
associated with decreased risk of cardiovascular 
diseases (CVD). Apart from CVD plasma and urine 
concentrations of homocysteine are also elevated in 
a rare autosomal recessive disorder; homocystinuria 
or hyperhomocytenemia. Homocystinuria 
clinically manifest as developmental delay, ocular 
abnormalities, thromboembolic disease and even 
osteoporosis. 
Laboratory Diagnosis of Homocystinuria or 
Hyperhomocysteinemia  
Homocysteine occurs in three forms; monomeric 
form Homocysteine, measured as plasma total 
Utility of Plasma Homocysteine in Identifying 
?????????? ??????????????????????????
?????????????????????????? ????
Clinical Chemistry
homocysteine (tHcy) by immunoassay or high 
????????????????????????????????????????????????
a dimer homocystine (homocysteine-homocysteine 
?????????? ????????????????????????????????
????????????????????????????????????????????????
?????????????????????????????????????????? ????????
????????????????????????????????????????????????????
including fasting, age, smoking, poor diet/cofactor 
????????????????????????????????????????????????????
???????????? ?????????????????????????? ??????????
??????????????????????????????????????????????
Contraceptives).
At clinical laboratory Aga Khan University plasma 
?????????????????? ???????????????????????
????????????????????????????????????????????????????
mainly for the evaluation of patients with CVD risk 
due to its atherogenic properties and monitoring 
patients with homocystinuria. The 
?????????????????????????????????????
for screening and monitoring patients 
suspected of having an inherited 
disorder of Met or Hcy metabolism 
including, Cystathionine beta-synthase 
??????????? ?????????????????????????
????????????????????? ??????????
??????????????????????????????
(Cbl) metabolism defects and 
???????????????????????????????????
???????????????????????????????????????
?????????????????????????????????????????
in Table 1.
While evaluating Homocystinuria, 
a non-IMD cause, vitamin B12 
?????????????????????????????????
???????????????? ???????????????
??????????????????????????????????????
folic acid can provide valuable clues to 
the etiology of Hyperhomocystenemia 
related disorders.
Methionine
S-Adenosylmethionine
Homocysteine
Cystathlonine
Cysteine
TRANSSULFURATION PATHWAY
S-Adenosylhomocysteine
MAT
CBS
CGL
SAHH
Methyltransferaso
Methyl
acceptor
Methylated
product
BHMT
Dimethylglycine
Betaine
THF
5-MTHF
5,10-MeTHF
MS
SHMT
MTHFR
FOLATE - DEPENDENT
REMETHYLATION
PATHWAY
FOLATE - INDEPENDENT
REMETHYLATION
PATHWAY
Figure 1: Metabolic pathway of Homocysteine 
(Reference: Barroso, Madalena & E. Handy, Diane & Castro, Rita. (2017). The Link between 
Hyperhomocysteinemia and Hypomethylation: Implications for Cardiovascular Disease)
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?????????????????????????????????????????? ????????????????????????????????????
??????????????????????????????????????
?????????????????????????????????????????????
?????????????????????????????
Cobalamin (CbI) 
metabolism defects
Transcobalamin II 
?????????
Vitamin B12 
?????????
CbIE (Cytosolic CbI transport defect - MTRR 
mutation)
CbIG (Cytosolic CbI transport defect - MTR 
Mutation)
CbIC (Cytosolic CbI transport defect – 
MMACHC mutation)
CbID (Cytosolic CbI transport defect – 
MMADHC mutation)
CbIF (Lysosomal CbI release defect – 
LMBRD mutation)
CbIJ (Lysosomal CbI release defect – ABCD4 
mutation)
Defective intestinal absorption of 
vitamin B12
Pernicious Anemia, Gut Bacterial metabolism, 
Gastroenteritis in very young infants, Short 
bowel syndrome, Malnutrition
Elevated Methionine and Homocysteine, 
Low Plasma Cystathionine with an 
increased Met:Cystathionine ratio
Elevated Plasma Homocysteine
Elevated Plasma Homocysteine and Low 
Methionine
Methionine Low to normal & Elevated Plasma 
Homocysteine
Methylmalonic Aciduria (MMAuria), Methionine Low to 
normal & Elevated Plasma Homocysteine
MMAuria, Elevated Plasma Homocysteine and Decreased 
Vitamin B12
Disorders Primary Defect Biochemical Findings
????????????????????????????? ????? ????? ?
Rare Bleeding Disorder
Dr Areeba Khalid
Haematology & Transfusion Medicine
???????????????? ????? ????????????????????
autosomal recessive coagulopathy.  It is rare in the 
general population [1:1,000,000]. It is primarily 
caused by defects of the factor V and VIII 
coagulation secretion pathways, including lectin 
mannose-binding protein type one (LMAN1), which 
was previously called ERGIC-53, and multiple 
??????????????????????????????????????????
Clinical Features 
Patients usually present with the severity of 
hemorrhagic symptoms, similar to that in patients 
????????????????????? ??????????????????????????
can be suggested that combined factor V and VIII 
????????????????????????????????????????????? ????
symptoms such as easy bruising, epistaxis, and 
gingival bleeding are frequently observed. Moreover, 
bleeding after tooth extraction, surgery, trauma, and 
menorrhagia and postpartum hemorrhage in females 
is also characteristic. 
Laboratory Findings
??????? ????? ??????????????????????????????????
normal platelet count and bleeding time but with 
prolonged PT and aPTT. Plasma levels of factor V & 
??????????????????????????????????????????????????
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a history of menorrhagia since six years. History of 
FFPs transfusion after normal vaginal delivery. There 
was no history of muscle hematomas, joint bleeds or 
CNS bleeding. She was not taking any medications 
on regular basis.
Physical examination revealed no petechial rash, 
hematoma or ecchymosis.
Laboratory investigations: Complete blood count of 
patient was normal, PT and aPTT was prolong (14.7 
sec and 59.3 sec, respectively). PT and aPTT were 
corrected after mixing the patient’s plasma with a 
healthy plasma in a 1:1 ratio. Fibrinogen and factor 
X levels were normal. Factor V and VIII levels were 
measured, and both levels were low (Eight percent 
and Fifteen Percent, respectively). According to 
?????????????????????????????????????????????????????
???????????????? ????? ??????????????
Treatment
??????????????????? ????? ???????????????????????
prophylaxis is not required and the patient is 
generally treated only when required. Factor V 
replacement therapy is administered by using fresh 
????????????????????????????? ????????????????
therapy is administered by using special factor 
VIII concentrates (either plasma-originated or 
recombinant factor VIII products). Desmopressin can 
be administered in case of mild bleeding.
Case study: 27 years old female, mother of two 
children, presented with history of bleeding from 
minor wounds. She had a history of fall in 2001 
for which she required surgical haemostasis for 
her wounds. There was history of excessive gum 
bleeding after tooth extraction six years back for 
which she required FFP transfusion. Patient also had 
Case details: Hematology department of Aga Khan 
University Hospital received a complete blood count 
with peripheral smear review of 11 month old baby 
girl from Sukkar. Her CBC showed: Hb: 5.6 g/dl, 
HCT: 18.9 percent, RBC: 2.08 x 10E9/L,MCV: 90.9 
??? ????????????? ?????????????????? ????????
x10E9/L, Platelets: 15 x10E9/L. Peripheral smear 
showed: normocytic normochromic red blood cells 
while neutrophils, lymphocytes and monocytes 
showed giant granules in cytoplasm and low platelet 
???????????????????????????????????????
Disorder in Phagocytic Function
Dr Sana Brohi 
Haematology & Transfusion Medicine
count (Figure 1-4). On acquiring history from father 
of the patient: she had a history of recurrent high 
grade fever since birth, abdominal distention for last 
3 months, nose bleed and sore throat and bruises over 
the body. Parents had consanguineous marriage. The 
child had two healthy elder sisters. On the basis of 
??????????????? ??????????????????????????????????
details suspicion of Chediak-Higashi syndrome was 
raised.
Figure 1
Figure 2
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Discussion
Chediak-Higashi syndrome (CHS) is a rare, 
??????????????????????????????????????????????
recurrent bacterial infections including pyogenic 
infections, oculocutaneous albinism that is present 
to a variable extent, progressive neurologic 
abnormalities, mild coagulation defects, and 
a lymphoma-like accelerated phase termed 
hemophagocytic lymphohistiocytosis (HLH).
Defective human gene ????????????????????
????????????????????? responsible, are part of 
?????????????????????????????????????????????????
proteins.The underlying defect in CHS is abnormal 
????????????????????????????????????????????????????
fusion of vesicles and failure to transport lysosomes 
to the appropriate site of action.Altered lysosomes/
granules are found in all cell types in CHS and are 
the hallmark of the disease:
Figure 3
Figure 4
i) Melanocytes contain enlarged pigment granules 
(melanosomes) that are not appropriately transferred 
to keratinocytes or epithelial cells, resulting in a 
variable degree of oculocutaneous albinism action.
????????????????????????????????????????????????????
cytotoxic T cells have enlarged mature secretory 
cytolytic granules, which do not appropriately 
release their contents in the setting of bacterial or 
viral infections, leading to impaired bactericidal 
and cytotoxic function, and neutrophils also have 
impaired chemotaxis.
iii) The number of platelet-dense bodies (serotonin-
?????????????????????????????????????????????????????
bleeding diathesis.
iv) Plasma membrane repair, which is a lysosome-
mediated process, is also impaired. 
Diagnosis: The diagnosis of CHS is typically 
suspected in patients with partial oculocutaneous 
albinism and recurrent pyogenic infections and 
is made by examining a peripheral blood smear 
??????????????????????????????????????????????
neutrophils, eosinophils, and other granulocytes 
. These large granules are found in all granule-
containing cells, including peripheral blood and 
bone marrow cells, melanocytes, peripheral and 
central nerve tissue, renal tubular epithelium, 
??????????????????????????????????????????
diagnosis is based upon genetic testing for 
mutations in the CHS1/LYST gene. 
The diagnostic criteria for CHS in the accelerated 
phase of the disease are the same as for 
hemophagocytic lymphohistiocytosis (HLH) 
due to other primary genetic defects and include 
????????????????????????????????????????????????
splenomegaly, cytopenia in at least two lineages 
in peripheral blood, hypertriglyceridemia and/or 
????????????????????????????????????????????
marrow, spleen, or lymph nodes, low or absent 
natural killer (NK) cell activity, hyperferritinemia 
and high levels of soluble interleukin (IL) two 
receptor.
RARE FACT
????????????????????????????
????????????????????????????????
?????????????????????? ??????????
rare diseases
RARE FACT
??????????????????????????????????????
????????????????????????????????
??????????????????
???? ??????????????????????????????????????
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The etiological agents of chromoblastomycosis 
are a group of relatively slower growing black 
fungi, including Exophiala species (E. dermatitidis, 
E. spinifera, E. jeanselmei), Cladophialophora 
carrionii, Cladosporium species, Fonsecaea spp. 
(F. pedrosoi), Phialophora spp. (P. verrucosa) and 
Rhinocladiella????????????????????????????????????????
????????????????????????????????????????????????????
therapy with both agents is reserved for severe or 
invasive disease. Role of conventional or cryo-
surgery is limited to small lesions as scarring may 
occur with larger areas of involvement. 
The criteria for cure of the disease depend on 
the severity of disease (See Table. Adapted from 
???????????????????????????????????????????
2017;30(1) Clinical Microbiology Reviews). 
Chromoblastomycosis is chronic progressive 
infection of the cutaneous and subcutaneous tissue 
???????????????????????????????????????????????
granulomatous lesion with micro-abscesses and 
hyperkeratosis. The pathognomic feature of 
chromoblastomycoses is the presence of muriform 
cells, also called “medlar bodies”, “copper pennies,” 
“chromo or fumagoid bodies,” and “sclerotic or 
meristematic cells”, in the tissue.
???????????? ???????????????????????????????????
????????????????????????????????????????????????
covered.  They may appear as nodular, verrucous 
or plaques, which may be cicatrical, i.e. circling a 
region, or not. Any type of plaques larger than 15 
cm and involving extensive regions of the body 
are considered severe; cicatrical lesions of any 
?????????????????????????????????????????????????
regions are considered moderately severe; while 
????????????????????????????????????????????????????
are mild severity. 
?????????????????????????????????????????
Dr Joveria Farooqi
Clinical Microbiology
Figure 1: Moderately severe lesion: 5-15 cm in size, verrucous cicatrical 
in one region of the body.
(Image from author’s personal collection) 
Figure 2: Muriform cell: brown pigmented structures with both 
transverse and vertical septae seen on gram stain of tissue biopsy of a 
verrucous lesion.
(Image from author’s personal collection)
The outcome of treatment depends on the host’s 
individual immune response (Th1 for mild and TH2 
for severe), and innate immunity status. Wrong or 
delayed diagnosis, disease severity, complications 
like secondary bacterial infection and malignant 
transformation and drug compliance are also 
important factors. Lesions with a large number of 
muriform cells and Fonsecaea species are more 
?? ???????????????
Lesion 
Nodular or 
verrucous
Cicatrical
???????
Severity 
Mild: 
Single <5 cm
Moderate: single or 
more nodular, 
verrucous, or plaque, 
alone/ combined, 
1-2 adjacent regions, 
5-15 cm
Severe: any type, 
alone/ combined, 
extensive regions
whether adjacent or 
not, >15 cm 
Criteria 
Clinical (2y follow up; 2 y 
without recurrence): 
 • Complete healing 
  with atrophic scarring, 
 • no pain and itching
Mycological (in 3 
consecutive monthly 
biopsies): 
 • Smear negative, 
 • Culture negative
Histologic (all 3 in 3 
consecutive monthly 
biopsies): 
 • No muriform cells and  
  microabscesses, 
? ?? ????????????????????
? ? ???????????????????
  replaces active 
  granulomatous 
? ? ?????????????????????????
 • atrophy of the 
  epidermis
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it is asymptomatic and presents after a fracture with 
minor trauma.
Histological features correspond with stage of 
??????????????????????????????????????????????????
capillary or cavernous vascular proliferation 
??????????????????????????????????????????
???????????????????????????????????????????
????? ????????????????????????????????????????
New bone formation is not seen. Radiologically 
intramedullary or subcortical lucent foci may be the 
earliest manifestation. This progresses to profound 
????????????????????????????????????????????????????
of compensatory osteoblastic activity or periosteal 
???????????????????????????????????????????? ????????
predict. Mostly progressive bone loss over years 
??????????????????????????????????????????????????
patients experience spontaneous arrest without 
complete bone loss.
??? ?????????????
Also known as Leri disease is a rare bone disease 
????????????????????????????????????????????????????
on the surface of existing bones. It typically occurs 
on the bones in one arm or leg, although it can also 
?????????????????????????????????????????????????
???????????????????????????????????????????????????
joint contractures 
and deformities 
in childhood or 
adolescence. 
Melorheostosis 
is of unknown 
etiology and it 
is considered a 
sporadic disease 
probably due 
to somatic 
mosaicism for a 
genetic defect. 
The pathology 
is essentially 
that of abnormal 
proliferation of 
Introduction
Rare diseases of bone include Gorham’s disease, 
melorheostosis, adamantinoma, Langerhans cell 
???????????????????????????????????? ??????????
myoepithelioma, schwannoma, melanotic 
neuroectodermal tumor of infancy, Erdheim-chester 
disease, Rosai-Dorfman disease, amyloidoma and 
Gaucher disease. In this article, we shall discuss 
radiological and histological features of following 
???????????????????????
??? ???????????????
Also known as Gorham vanishing bone disease and 
phantom bone disease, is a very rare skeletal disease 
??????????????????????????????????????????????????
and usually progressive destruction of one or more 
bones. This destruction has been thought to be 
attributed to uncontrolled proliferation of thin-
walled vascular channels within bone, which leads to 
resorption and replacement of bone with angiomas 
???????????????
The disease occurs in children and young adults and 
???????????????????????????????????????? ???????????
sites of involvement are pelvic and shoulder girdle, 
skull, jaw, ribs, and spine. The symptoms vary 
depending on the bones involved. In half of patients, 
?????????????????????????????????????
Diseases of Bone
Dr Nasir Ud Din and Dr Dawar Khan
Histopathology and Radiology
Figure 1. Radiological and histological images of Gorham’s disease
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Radiologically , it appears as a multilocular or 
slightly expansile osteolytic cortical lesion. This 
??????????????????????????????????????????????????????
areas of sclerosis. Lesions tend to have an eccentric 
epicentre and a lack of periosteal reaction. There 
may be locally aggressive disease at presentation. 
Adamantinomas are locally aggressive tumor and 
are extremely slow growing with the potential to 
?????????????????????????????????????????????????????
percent.
??????????????????? ????????????
Langerhans cell histiocytosis of the bone is a relatively 
?????????????????????????????????????????????????
neoplastic proliferation and accumulation Langerhans 
cells within various tissues (bone marrow, skin, central 
nervous system, lung, liver, spleen, lymph nodes) 
?????????????????????????????????????????????????????
percent of all osseous lesions.
Radiological features depends on which bone is 
involve. In skull, solitary or multiple punched out 
lytic lesions without sclerotic rim. Double contour 
or beveled edge appearance may be seen due to 
asymmetrical involvement of the inner and outer 
tables (hole within a hole). 
In mandible, irregular radiolucent areas mostly 
????????????????????????????????????????????????????
loss of lamina dura. In spine, vertebra plana: most 
common cause of vertebra plana in children; more 
often in thoracic spine. 
In long bones, depends on phase of disease which 
is imaged. Permeative and aggressive appearing 
lesion. Mainly involves diaphysis or metadiaphysis 
and respects growth plates. Endosteal scalloping, 
periosteal reaction (in healing phase it can appear 
compact haversian bone distorting the contour of 
bone periosteal and endosteal surfaces.
Radiological features include thickening of the 
endosteum and periosteum. Peak age of presentation 
is 05-20 years. May be monostotic or polyostotic. 
Sclerotic lesions of cortical bones, usually in the 
diaphysis, that resemble “candle-wax-dripping”. 
Cortical hyperostosis with an undulating appearance 
?????????????????????????????????????????????????
lesions that may calcify adjacent to involved bone. 
May grow to compress nerves. There is no curative 
treatment for melorheostosis. The disease is not 
???????????????????????????????????????????????????????
due to chronic pain that can worsen or reappear, even 
after surgery.
??? ???????????
Adamantinoma is an extremely uncommon bone 
tumor accounting <1 percent of primary malignant 
bone tumors. It almost exclusively occurs in tibia 
????????????????????????????????????????????????
more common in males with a median age of 25-35 
years.
The clinical presentation is swelling with or without 
pain usually years prior to diagnosis. Histologically, 
??????????????????????????????????????????????????
?????????????????????????????????????????????????
???????????????????????????????????????????
morphological patterns of epithelial cells are seen, 
basaloid, squamoid, tubular and spindle. The well-
??????????????????????????????????????????????????
????????????????????????????????????????????????????
epithelial nests.
Figure 2. Radiological and histological images of Melorheostosis 
Figure 3. Radiological and histological images of Adamantinoma.
?????
19
VOL. 45, ISSUE 1FEBRUARY 2019
collagen. The cells are arranged in fascicles 
and pleomorphism and atypia is minimal or 
absent and mitoses are rare.
On radiological imaging it typically seen as a 
lytic bone lesion with a geographic pattern of 
?????????????????? ??????????????????????????
transition and non-sclerotic margins. Internal 
pseudotrabeculation seen in >90 percent. No 
??????? ??????????????? ????????????????????
bone from gradual apposition of periosteal new bone 
formation noted in 90 percent of cases.
???????????????????????????????????????????????????
???????????????????????????????????????????????????
much lower after complete excision.
as solid benign periosteal reaction), cortical thinning, 
intracortical tunneling, and associated soft tissue mass.
Prognosis of Langerhans cell histiocytosis is 
???????????????????????????????????????????????????
especially if it is a solitary lesion. Majority of such 
??????????????????????????????????????????????????
one-two years.
???????????????????????
????????????????????????????????????????????????????
???????????????????????????????????????????????????
????????????????????????????????????????????????????????
one of the rarest primary bone tumors accounting for 
<0.1 percent of primary bone tumors. Peak incidence 
is second to third decade of life and most commonly 
??????? ????????????????????????????????????????
mandible. Most cases present with pain and swelling.
Histological features are similar to soft tissue 
???????????? ??????????????????????????????????????
Figure 4. Radiological and histological images of Langerhans cell histiocytosis
?????????????????????????????????????????????????????????????????????
ASMA
????????????????????????????????????????????????????????
a similar mechanism to multiply within mammalian 
cells. These bacteria cause respiratory disease in 
???????????????????????????????????????????????????
water containing the bacteria or aspirates water 
containing the bacteria.
Microbial Etiology
L. pneumophila multiplies at temperatures between 
25 and 42°C, with an optimal growth at 35°C. 
Introduction
Legionellosis is an infrequently encountered form 
of atypical pneumonia caused by a bacterium 
Legionella pnemophila. Failure to diagnose 
legionellosis is largely due to a lack of clinical 
??????????????????????????????????????????????????
??????????????????????????????????????????????????? ?????
to grow on culture, and not easily detected on 
gram stain. They are faintly staining gram-negative 
bacilli found in freshwater environments, living as 
Legionellosis
Ms Sidra Laiq
Clinical Microbiology
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is slow growing (three-seven days). The medium 
??????????????????????????????????????????????????
????????????????????????????????????????????????????
without selective agents. Susceptibility testing is not 
recommended. PCR on lower respiratory samples 
may also be helpful. 
Urine Antigen Detection Test
Urinary antigen detection is popular and strongly 
recommended in clinical practice guidelines. The 
most recent method for detecting antigenuria is the 
immunochromatographic (ICT) membrane assay. 
The test is simple to perform and does not require 
special laboratory equipment, and results can be 
obtained within 15 min. Urine antigen detection tests 
are rapid and easy and are widely used for detection 
of other causes of pneumonia such as Streptococcus 
pneumoniae.
Treatment
????????????????????????????????????????????????
community acquired pneumonia should include 
???????????????????????????????????? ????????????
?????????????????????????????????????????????????????
Legionellosis.
??????????????????????????????????????????????
humidity necessitates maintenance of thermally 
altered aquatic environments which can shift the 
????????????????????????????????????????????????????
in rapid multiplication of legionellae in the water and 
generation of aerosols in the air circulatory systems, 
translating into human disease. 
Clinical Presentation
Legionellosis classically presents as two distinct clinical 
entities, Legionnaires’ disease, a severe pneumonia 
with multisystem disease usually in older patients, and 
???????????????????????? ??????????????????????????????
of Legionnaires’ disease include fever, nonproductive 
cough, headache, myalgias, rigors, dyspnea, diarrhea, 
?????????????? ??????????????????????? ???????????
with Legionnaires’ disease, similar to other forms of 
atypical pneumonia. The key to diagnosis is performing 
appropriate microbiologic testing when a patient is in a 
high-risk category.
Diagnosis of Legionellosis
Serologic diagnosis of Legionnaires’ disease was 
once the most frequently used diagnostic test. 
Culture of legionella is not easy and the organism 
using DBS thyroid stimulating hormone (TSH) 
testing. The DBS sample should be collected after 
48-72 hours of birth. It can be collected after 24 
hours of birth in case of early discharges. If medical 
complication require transfusion, a specimen should 
be collected before transfusion and another specimen 
should be collected 48-72 hours after transfusion. In 
baby with very low birth weight repeat sampling is 
advised as follows:
a) Birth weight <1000 g – Repeat sample no later 
 than 6 weeks.
b) Birth weight 1000g-1499 g– Repeat sample no 
 later than 4 weeks
Because of the complexity and diversity of the 
specimens that might be encountered and the 
Collection of a good quality DBS specimen from 
a newborn is of utmost importance for generating 
accurate laboratory results. A poorly collected or an 
unsatisfactory specimen requires retesting; additional 
follow-up of the newborn, which, if not completed in a 
timely manner could result in missed or late diagnosis. 
This places an unnecessary burden on the newborn 
screening (NBS) system, trauma to the newborn and 
anxiety to the parents. The turnaround time is critical 
while reporting a newborn screening specimen, if 
treatments to alter the adverse consequences of a 
condition (such as irreversible brain damage or death) 
are to commence in a timely manner. 
At Aga Khan University Hospital, NBS program 
is established for congenital hypothyroidism (CH), 
????????????????????????????????????
Newborn Screening
??? ???????????
Chemical Pathology 
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? ?????????? ??????????????????????????????????????
 might cause hemolysis of the specimen or result  
? ?????????????????????????????????????????????????
 which might adversely 
? ???????????????????????
??? ????????????????????????????
 so that a target circle cannot 
? ?????????????????????
 sampling using a new  
 circle. DO NOT go back on 
 the previously collected 
 spot as it will result in 
 layering.
9. Repeat, until you have collected enough blood  
? ?????????????????????????????????????????????????????
 card is allowed to dry in air at ambient 
 temperature (15-22°C). Cards must not be   
 stacked on top of one another while drying.
10. Avoid touching or smearing  the blood spots   
? ?????????????????????????????????????????????????
? ???????????????????????????????????????????????
 as a drying rack for a 
 minimum of three to four 
 hours at ambient 
 temperature. 
???? ?????????????????????????????
 be dried near an open 
 window; as sunlight, dust  
? ?????????????????????????
 insects may come in contact  
 with the DBS during the 
 drying procedure.
12. Do not heat, stack or allow  
 DBS to touch other surfaces  
? ??????????????????????????????????????????????
 paper in direct sunlight or in area with 
 temperature >25oC. 
13. Once completely dried (brick red color), insert  
? ????????????????????????????????????????????? ???
 desiccant packets and humidity indicator cards. 
 Label contents of bag, seal and send to 
 laboratory immediately, no later than 24 hours.
14. Avoid leaving it in a vehicle, as sun and heat 
 will deteriorate DBS. Avoid placing spots in an 
 malfunctioning refrigerator where water may 
 drip on or soak the spots
?????????????????????????????????????????????????
their interpretation, the specimen criteria and below 
described handling procedures should be strictly 
followed.
DBS Specimen Collection Procedure
1. Take consent before DBS  
 sample collection. 
 Clearly label each card  
 with appropriate 
? ??????????????????????
2. Take blood from baby’s  
 heel, which should be 
 gently warmed from the 
? ??????????????????????????
 Clean area with alcohol 
 swab and allow to air-dry. 
3. A sterile lancet is then  
 used to make the puncture, 
 to a depth not greater than 
 two mm.
??? ????????????????????????????
 forms may be wiped away 
? ?????????????????????????????
 remove any contamination. 
 The foot should not be 
? ?????????? ????????????
? ????????????????????????????????????????????????
? ???????????????????????????????????????????????????
? ????????????????????????????????????????????????
? ???????????????????????????????????????????????????
? ?????????????????????????????????????????????
? ????????????????????????????????????????????
 saturate a circle. 
??? ?????????????????????????
 circle completely and 
 saturate the paper right  
 through. Only one drop of 
 blood should be applied 
 to each circle, and each 
? ???????????????????????????????????????????????
 paper against the puncture site.
??? ?????????????????????????????????????????????????
 Do not layer successive drops of blood or apply 
 blood more than once in the same collection 
 circle.
??? ??????????????????????????????????????????????
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• Contaminated sample: 
 another liquid has been in contact with the card 
? ????????????????????????????????????????
 
• Sample not dried properly: not air dried for 3-4 
 hours, card placed in plastic bag.
• Serum rings: not wiping alcohol from heel 
 before puncture, card contaminated with alcohol, 
? ?????????????????????????????????????????????
 collect sample. 
?? ??????????????????????????????????????????????????
 touching paper to blood several time. 
Acceptable Sample
???????????????????????????
all circles if collection 
????? ???????????????
unnecessary trauma to the 
baby or parents. Three good 
???????????????????????????
Unacceptable Sample
?? ????????????????????????
 not soaked through card 
 properly.
?? ??????????????????????
 enough circles.
incidence rates, for example, Ahmed et al. reported 
3 patients had CH out of the 767 newborns screened, 
a mathematically estimated incidence of CH 
could be one in 255 births. However, their sample 
encompassed a private sector hospital only and not 
the general population, thus leading to potential 
selection bias. 
The goal of newborn screening programs is to 
?????????????????????????????????????????????????????
Congenital hypothyroidism (CH) is one of the most 
common, preventable causes of mental retardation 
?????????????????????????????????????????????????
birth. In most cases, the disorder is permanent. Less 
commonly, the altered neonatal thyroid function 
is transient, attributable to the transplacental 
passage of maternal medication, maternal blocking 
??????????????????????????????????????????????????????
hypothyroidism poses a serious issue in infants as the 
????????????? ?????????????????????????????????????
signs and symptoms may be so subtle that they can 
be easily missed. 
In the developed world, newborn screening 
programme for CH are considered vital elements 
of the healthcare system. In contrast, in developing 
countries, like Pakistan, newborn screening is not 
traditional and hasn’t been established as a national 
screening programme yet. Screening tests for CH are 
preferably done after 2 days (ideally 48-72 hours of 
birth) when the thyroid stimulating hormone (TSH) 
???????????????????????????????????????????????????
seen in the immediate post-delivery period. 
The CH incidence reported in literature is 1:1600 
to 1:2000. Some studies have reported even higher 
Newborn Screening Program for Congenital 
Hypothyroidism
Dr Hafsa Majid
Clinical Chemistry
????????? ??????????????? ?????????? ??????????????????????
For Monitoring 
Recheck T4, TSH 
at
Goal of therapy
 
Assess 
permanence of 
CH
2–4 weeks after initiating treatment 
?????????? ???????????????????? ?????
Every 3–4 months between 6 months and 
3 y of age
Every 6–12 months from 3 y of age to end 
of growth
?????????????????? ???????????????????
in upper half of reference range
If initial thyroid scan shows ectopic/absent 
gland, CH is permanent
If initial TSH is <50 mU/L and there is no 
increase in TSH after newborn period, then 
??????????????????????????????????????????
?????????????????????????????????????????
CH
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samples are collected within 48-72 hours of birth 
(after 24 hours of birth in case of early discharge) 
and tested for neonatal TSH. Abnormal results 
????????????????????????????????????????????
???????????????????????????????????????????????????????
communicated back to the physician or hospital 
?????????????????????????????????????????????????
diagnostic algorithm for CH is shown in Figure 1.
weeks of life. Treatment consists of a daily dose of 
thyroxine, available as a small tablet. The tablet is 
crushed and given to the infant with a small amount 
of water or milk. The TSH levels are checked 
regularly to maintain the right dose. 
At Aga Khan University Hospital newborn screening 
program is established for CH. The dried blood spot 
Figure 1: Algorithm for Diagnosis of Congenital Hypothyroidism
Conversion factor: 1 mIU/l = 1 uIU/ml; Serum TSH ~ 0.45 DBS-NTSH
health bodies and interventional education modules 
?????????????????????????????????????????????
regarding CH and newborn screening in general.
It is need of time that a national action plan is 
developed for implementation of NBS program for 
CH across Pakistan in consensus with all provincial 
to hyper secretion of corticotrophin-releasing 
hormone (CRH) and adrenocorticotropic hormone 
(ACTH) and consequential hyperplasia of the 
?????????????????????????????? ??????????????????????
as a classic (more severe) or nonclassic (less 
Congenital adrenal hyperplasia (CAH), is an 
?????????????????????????????????????????????????
involved in adrenal steroidogenesis due to mutations 
??????????????????????????????????????????????????
each disorder is impaired cortisol secretion, leading 
A Laboratory Insight into Congenital Adrenal 
Hyperplasia
Dr Sibtain Ahmed
Clinical Chemistry
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can be undertaken for CAH diagnosis or monitoring 
are: 
????????????????????????????????????????
a. Screening: A 17-OHP test may be ordered as a 
 screening test of choice for newborn screening to 
? ????????????????????????????????????????????
 The test may be repeated if the screening result  
? ????????????????????????????????????????????????????
b. Diagnosis: Measurement of 17-OHP in the blood 
 may be used to aid in the diagnosis of CAH in 
 older children and adults who may have a milder, 
 “late-onset” form. 
c. Monitoring: If someone is diagnosed 
with CAH, a 17-OHP test may be used 
???????????????? ????????????????????????
of treatment.
???? ?????????????????????? 
Administration of 250 ug of cosyntropin 
also known as synecthin provides a 
pharmacologic stimulus to the adrenal 
???????? ?????????????????????????????
?????????????????????????????????
21OHD may be determined based on 
baseline and stimulated values of 17-
OHP, the immediate precursor to the 
??????????????????????
?? ???????????????????????????????????????? 
???????????????????????????????????????????????
is associated with excessive DHEA-S production. 
Lesser elevations may be observed in 21-OHD 
??????????????????????????????????????????????
steroidogenic acute regulatory protein or 17 
??????????????????????????????????????????????????
low DHEA-S levels.
?????????????????????? Approximately 10 percent 
?????????????????????? ??????????????????????????
testosterone, a potent androgen. Consequently 
pronounced elevations are found in CAH. 
???????????????? Elevated plasma renin activity 
values, particularly the ratio of renin to aldosterone, 
are markers of impaired mineralocorticoid synthesis. 
?????????????????????? especially sodium and 
potassium are routinely done in monitoring of CAH 
patients. 
?????????? ???????  is tested to evaluate for 
??????????????????????????????????????????????????
an extreme sensitivity to insulin leading to low blood 
glucose levels.
severe) type. Approximately 75 percent cases with 
??????????????????????????????????????????????????
form that includes decreased aldosterone and leads 
?????????????????????????????????????????????????
potassium which is potentially life-threatening. 
Literature review suggests that more than 90 percent 
of cases of CAH are caused by a defect in the 
???????????????????????????????????????????????
by a mutation in the CYP21A2 gene. Four other 
???????????????????????????????????????????????
pathwayaccount for the remaining cases as depicted 
in Figure 1.
List of Tests available for Diagnosis of CAH at 
AKUH Laboratory
Lab workup of CAH essentially requires the 
measurement of a panel of steroids. Patients with 
CAH due to steroid 21-hydroxylase defects/ 
??????????????????????????????????????????????
androstenedione. Moreover 17-OHP levels are 
usually even higher, whereas cortisol levels are low 
??????????????????????????????????????????
??????????????????????????????????????????????????
??????????????????????????????????????????????????
of cortisol, aldosterone and renin. Whereas the 
levels of 11-deoxycorticosterone (11-DOC) are 
???????????????????????????????????????????????
????????????????????????????????????????????????
to corticosterone and aldosterone. 
?????????????????????????????????????????
????????????????????????????????????????????????
by hypertension in most cases. It shows elevated 
levels of pregnenolone, progesterone, 11-DOC and 
corticosterone. However renin, aldosterone and 
??????????????????????????????????????????????????????
Figure 01: - Pathways of Steroid Biosynthesis
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??? ???????????????? Karyotyping and pelvic and 
???????????????????????????????????????????????
diagnostic modalities. Kidney function and liver 
function tests may also be tested during management 
of these patients.
Burden of CAH in Pakistan
 
The true incidence of CAH in Pakistan remains 
???????????????????????????????????????????
screening program, lack of diagnostic testing 
facilities and disease awareness in the society and 
?????????????????????????????????????????????????????
A study from our center revealed that of the 152 
children registered for 17-hydroxyporegeterone 
(17-OHP) testing, sixty-three (41.4 percent) were 
diagnosed with CAH. Among these salt wasting, 
??????????????????????????????????????????
was found in 40 (63 percent), 18(29.0 
????????????????????????????????????????
respectively. Another study from Pakistan 
showed variable frequency of referrals 
?????????????????????????????????????
Higher frequency of cases with suspected 
CAH was observed from Sindh (23.7 percent) as 
compared to other provinces. These studies show 
that CAH is not an uncommon disease, thus a well-
structured and appropriate screening program of 
CAH is the need of time.
???????????????????????????????????????????????????????
?????????
???????
???????
???????
Cortisol
?
?
?
ACTH
?
?
?
Blood 
Pressure
?
?
?
Androgen
?? ??????
?? ??????
?? ??????? ?
Testicular
Estrogen
-
-
?
transport. The gene known as CHS1/LYST resides 
on chromosome 1q42-43 & regulates lysosome 
???????????????????????????????????????????????????
from mild to severe. The fair skin has slate-grey hue. 
Hair including eyebrows & eyelashes appear metallic 
silver. The iris may appear blue. Photophobia 
& sunburn are common. The increased risk of 
infection is due to impaired phagocytic function 
of leukocytes & other cells involving lysosome 
defects. The accelerated phase in childhood 
manifests as pancytopenia, hepatosplenomegaly 
??????????????????????????????????????????????????
This may be followed by death. Simple light 
microscopy of hair shaft is useful, non-invasive & 
??????????????????????????????????????????????????????
melanin pigment granules as opposed to irregularly 
?????????????????????????????????????????????
microscopy reveals polychromatic appearance 
as opposed to monotonous appearance in GPS. 
Skin biopsy highlights reduced or absent melanin 
in basal layer of epidermis & hair follicle. Giant 
melanosomes may be seen as clumps of enlarged 
melanin pigment. Von Kossa stain for melanin 
pigment will be used to demonstrate these clumps. 
In less severe cases granules may be seen in dermal 
macrophages, endothelial cells or within interstitium.
Silver Hair Syndromes
Silver or grey hair disorders in childhood are 
autosomal recessive manifesting as reduced 
pigmentation of hair, skin combined with 
???????????????? ???????????????????????????
Three disorders are included 
1:  Chediak-Higashi syndrome (CHS); 
2: Elejalde syndrome (ES); 
3: Griscelli syndrome (GPS). 
Clinical features may be overlapping, especially 
CHS and GPS need skin biopsy, hair shaft & 
peripheral blood examinations to make the diagnosis. 
???????????????????????????????????????????????????
gene mutation by chromosomal analysis will help.
??????????????????????????????????????
??????????????????????????????????????????????
albinism, recurrent pyogenic (bacterial) infections & 
abnormal giant granules in leukocytes & precursors. 
Bleeding tendency & neurological dysfunctions 
are also noted. Pigmentory abnormalities in CHS 
are due to impaired transfer of melanosomes 
from melanocytes to keratinocytes resulting from 
gene mutation involving intracellular organelle 
Rare Disease in Dermatopathology
Dr Saira Fatima
Histopathology
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of hypogammaglobulinemia as well. Accelerated 
phase with hemophagocytic disorder is seen in 
advanced stage. Type three has only pigmentory 
abnormalities. Therefore, prognosis of GPS one & 
two is poor than GPS three. The treatment of GPS 
two is on similar lines as in CHS. GPS three does not 
require any treatment.
Hair shaft light microscopy demonstrates large 
unevenly distributed granules of melanin pigment 
?????????? ?????????????????? ????????????????
monotonous whitish appearance. Skin biopsy 
highlights enlarged hyper pigmented melanocytes 
but absent pigment in keratinocytes.
???????????????????????????????
The syndrome has been designated as GPS 1 by 
some of the authors. The gene defect involves 
MYO5A. The partial albinism (silvery hair & 
hypo pigmented skin) is associated with severe 
neurological defects of CNS. The later manifest 
?????????????????????????????????????????????
Hence the other name of Neuroectodermal 
melanolysosomal disease. Immunological 
functions are intact.  
Hair shaft pigmentory features are same as in GPS 
as large irregular clumps of melanin. Skin biopsy 
changes are also same i-e melanin granules of 
??????????????? ????????????????? ?????????????????
absent melanin in keratinocytes.
???????????????????????????????????
The partial albinism is combined with 
???????????????????????????????????????????
???????????????????????????????????????????
(OMIM 214450), gene defect MYO5A, without 
immunological abnormalities; Type two (OMIM 
607624), gene RAB27A, with immunological 
impairments; Type three (OMIM 609227), gene 
MLPH, without immunological or neurological 
????????????????????????????????????????? ???????????
transfer from melanocytes to keratinocytes, similar 
to CHS. However, abnormal cytoplasmic granules in 
leukocytes of CHS are absent in GPS which makes 
????????????????????????????????????
Clinical features overlap with CHS, including 
silver-grey hair, pale skin & susceptibility to skin 
tanning after sun exposure. GPS one patients also 
??????????????????????????????????????????????????
immunological & hematological abnormalities. 
There is history of severe infections due to absent 
delayed-type cutaneous hypersensitivity & defective 
natural killer cell function. There have been reports 
RARE FACT
??????????????????????????
??????????????????
??????????????????? ????
??????????????????????????
??????
RARE FACT
???????? ????????????????????
???????????? ???????????????
??????????????????
???????????????????? ?????
???????????????????????????
?????
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urinary saccharides. Honey, Chocolate, milk, juices 
and cereals may be a cause of false positive results 
(Table 1). Retesting will be recommended in these 
cases.
??????????????????? ??????????????????????? 
there are various types of saccharides. 
Monosaccharides are the sugar units that cannot 
????????????????????????????????????????????????????
two major classes of monosaccharide’s aldoses 
are ketoses (Table 2). Disaccharides are the sugars 
containing two monosaccharide units linked 
by glycosidic bond. The three most common 
disaccharides are shown in Table 2.
Sugar chromatography in random urine can be 
used in screening for some inherited metabolic 
disorders and may also aid in evaluation of defects 
in renal function. Thin layer chromatography (TLC) 
is used to separate the components of a mixture 
using a thin stationary phase supported by an inert 
backing. Analysis of sugars is carried out mainly 
???????????????????????????????????????????????????
paper. The principle of separation is adsorption 
and involves a stationary phase consisting of a thin 
layer of adsorbent material, usually silica gel & 
organic solvents as mobile phase. The sugars are 
?????????????????????????????????????????????????????
chromatographed on the same plate. This test may 
be done following a positive screen for reducing 
substances in urine for qualitative estimation of 
the sugar/ sugars present. It may aid the diagnosis 
of classical galactosaemia, sucrose malabsorption, 
lactose intolerance or fructosuria/hereditary fructose 
intolerance described below. 
Limitations of the test: Please note microbial 
contamination can lead to uninterpretable patterns of 
Screening for Carbohydrate Metabolism 
Disorders by Sugar Chromatography in Urine
??? ???????????????? ???????????
Clinical Chemistry
Table 1: Food Sources of Various Sugars
Dietary Source
Honey
Milk, chocolate
Presweetened 
cereals
Raw cane sugar
Sugars
Fructose, Glucose, Sucrose
Fructose, Glucose, Sucrose, Lactose, Maltose
Glucose, Fructose, Sucrose, Maltose
Glucose, Fructose
Table 2: Description of Mono and Disaccharides
Description 
Sugars containing an aldehydic group
Sugars containing a ketonic group
?????????????????????????????????????????????????????????
???? ??????????????????????
???????????????????????????????????????????????????????????
??????????????????????
???????????????????????????????????? ??????????????????????
Mono/ Disaccharide
Aldoses
Ketoses
Lactose
Sucrose
Maltose
Examples
Glucose, Galactose, Mannose, Ribose 
Fructose
Glucose + Galactose
Fructose + Glucose
Glucose + Glucose
Differences between Reducing and Non-
reducing Sugars: Sugars having a free aldehydic 
or ketonic group are known as reducing sugars. 
A reducing sugar acts as a reducing agent and 
can donate electrons to another molecule and 
????????????????????????????????????????????????
group. A non-reducing sugar is that does not 
have a free aldehydic or ketonic group and is 
????????????????????????????????????????????
common dietary monosaccharide’s galactose, 
glucose and fructose are all reducing sugars 
while sucrose is the most common non reducing 
sugar (Table 3).
Table 3: Examples of Reducing and Non Reducing Sugars
Reducing Sugars
• Galactose
• Glucose
• Lactose,
• Fructose
• Xylose,
???????????????????
Sucrose
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careful handling of temperature sensitive hepatic 
??????????????????????????????????????????????????
are not available in Pakistan thus needs to be out-
sourced to overseas laboratories, which is extremely 
challenging and chances of losing the precious 
hepatic tissue collected after an invasive procedure 
are very high. Molecular testing (gene testing) was 
?????????????????????????????????????????????
activity studies and clarify ambiguous results. In 
the last decade molecular testing has become the 
???????? ??????????????????????????????????????
of molecular testing are numerous and include the 
following:
• Molecular analysis obviates the need for invasive 
 biopsy.
?? ????????????????????????????? ?????????????
? ??????????????????????????????????????????????
 based testing does not require extremely careful 
 handling of sensitive specimens.
?? ????????????????????????????????????????????????
? ??????????????????????????????????????????????
? ?????????????????????????????????????????????????
? ???????????????????????????????????????????????
? ?????????????????????????????????????????????????
?? ?????????????????? ?????????????????????????????
? ??????????????????????????????????????????????
? ??????????????????????????????????????????????????
 to develop disease.
• Molecular testing can be used for prenatal 
? ??????????????????????????????????????????????????
 familial variant testing to at-risk couples and 
 family members.
The glycogen storage diseases (GSDs) are a group 
of inherited metabolic disorders that result from
????????????????????????????????????????????????????
either glycogen synthesis or glycogen degradation. 
GSDs can be divided into two groups; the 
hepatic group, which present as hypoglycemia 
and hepatomegaly and the muscle group, which 
presents as neuromuscular disease and weakness. 
????????????????????????????????????????????????????
???????????????????????????????????????????????????
??????????????????????????????????????????????????
???????????????????????????????????????????????
clinical phenotype including doll-like facies, 
failure to thrive/short stature, hepatomegaly and 
biochemical phenotype including fasting ketotic 
hypoglycemia, lactic academia, raised alanine 
transaminase with or without hypertriglyceridemia 
and hyperuricemia. 
Traditionally hepatic group of GSD has been 
diagnosed using a combination of clinical 
symptoms, biochemical features and hepatic histo-
pathological features of fatty changes with medium 
to large lipid vacuoles, nuclear hyperglycogenation 
???????????????????????????????????????????????????
tissue include hepatic electron microscopy and 
?????????????????????????????????????????????????
hepatic GSDs. The histopathological features are 
??????????????????????????????????????????????????
???????????????????????????????????????????????????
????????????????????????????????????????????????????
liver tissue collected via liver biopsy and needs 
to be transported to the laboratory with extremely 
Diagnosing Glycogen Storage Disorder – 
Liver Biopsy or Molecular Testing
?????????? ??????
Department of Paediatrics & Child Health 
A positive reducing substance from a patient 
other than a diabetic must be followed up by 
????????????????????????????????????????????????
This is particularly helpful in the preliminary 
investigation of conditions such as Galactosemia 
and Fructosaemia. 
What is the utility of doing urine dipstick 
testing? Glucose and galactose bands appear 
same on TLC. Therefore whenever a band in 
glucose or galactose region is noted on TLC plate 
?????????????????????????????????????????????????
sugar present urine dipstick testing is done before 
reporting. In the presence of glucose in urine 
dipstick is positive for reducing substance and 
absent in the presence of galactose. The glucose 
??????????????????????????????????????????????
oxidase / peroxidase reaction on the dipstick and 
????????????????????????????????????????????????????
per kit insert). 
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Table 1: Summary of the Glycogen Storage Disorders 
Enzymes 
Glycogen Synthase 
Glucose-6-phosphotase
Glucose-6-phosphotase transporter
?????????????????
LAMP-2 protein
Amylo-1,6-glucosidase
Amylo-1,4 ?1,6 transglucosylase 
Glycogen phosphorylase (muscle)
Glycogen phosphorylase (liver)
Phosphofructokinase 
????????????????????????????????
????????????????????????????????
????????????????????????????????
????????????????????????????????
Glucose transporter-2
Types
GSD 0
GSD Ia
GSD Ib
GSD IIa
GSD IIb
GSD III
GSD IV
GSD V
GSD VI
GSD VII
GSD IXa
GSD IXb
GSD IXc
 GSD IXd
GSD XI
Genes
GYS2
G6PC
SLC37A4
GAA
LAMP2
AGL
GBE1
PYGM
PYGL
PFKM
PHKA2
PHKB
PHKG2
CLAM1
SLC2A2
The Next-Generation Sequencing (NGS), which 
??????????????????????????????????????????????
?????????????????????????????????????????????????
in a single DNA sample. This is a rapid and a 
much cost effective way of not only diagnosing 
GSD but also differentiate different types of 
GSDs in absence of the invasive procedure of 
liver biopsy. NGS has now become the gold 
standard to confirm a suspected diagnosis of 
GSD.
high mortality rate and usually presents before 
the age of 6 months with failure to thrive, 
???????????????????????????????????????????????
nephrocalcinosis, muscular hypotonia, fractures, 
craniosynostosis and respiratory failure. However, 
dominant childhood and adult hypophosphatasia may 
have only subtle symptoms such as chronic pain and 
early tooth loss.
Laboratory Workup for Hypophosphatasia: 
Low alkaline phosphatase (ALP) interpreted 
????????????????????????????????????????????????
biological hallmark of HPP. Low ALP in blood 
serum is expected to be present lifelong for any 
patient with HPP. Serum ALP are a group of 
??????????????????????????????????????????????????
of phosphoesters to release inorganic phosphate. 
??????????????? ????????????????????????????????????
ALPs (placenta, intestine, germ cell); and a tissue 
??????????? ??????????????????????????????
Overview of Hypophosphatasia: Hypophosphatasia 
(HPP) also known as Rathbun syndrome is a rare, 
inherited, potentially life-threatening bone disorder. 
It is caused by inactivating mutations in the liver/
bone/kidney alkaline phosphatase gene (ALPL) and 
????????????????????????????????????????????????
alkaline phosphatase (ALP) activity. Depending 
?????????????????????????????????????????????
an autosomal recessive or autosomal dominant 
manner. The prevalence of severe forms of the 
disease has been estimated at 1/100 000. Based 
on age at presentation and severity of symptoms, 
?????????????????????????????????????????????????
lethal, 2. Prenatal benign, 3. Infantile, 4. Childhood, 
5. Adult and 6. Odontohypophosphatasia (limited to 
dental manifestations). 
Clinical Presentation of patients with 
Hypophosphatasia: Patients with the recessive 
perinatal and infantile hypophosphatasia have a 
Hypophosphatasia a Rare Skeletal Disorder
Dr Siraj Muneer 
Clinical Chemistry
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Management of Hypophosphatasia: The treatment 
?????????????????????????????????????????????
??????????????????????????????????????????????????
???????????????????????????????????? ??????????????
specialists, pediatricians, orthopedic surgeons, 
dental specialists and other healthcare professionals. 
??????????????????????????????????????????????????
medical treatment for perinatal, infantile, and 
juvenile-onset HPP by the U.S. Food and Drug 
Administration (FDA). It is a bone-targeted form of 
TNSALP replacement therapy.
expressed in tissues including bone, liver, and 
kidney, encoded by the ALPL gene on chromosome 
(1). Its major role is cleavage of extracellular 
substrates such as inorganic pyrophosphate (PPi) and 
pyridoxal-50 -phosphate (PLP). 
The diagnosis of hypophosphatasia is made on 
the basis of clinical, biochemical and radiologic 
features. The hallmark biochemical features are low 
serum ALP, elevated  PLP and elevated Urinary 
phosphoethanolamine (PEA) levels.  
Usual and Unusual causes of 
Hyperammonemia
Dr. Sibtain Ahmed, 
Clinical Chemistry
 
 
 
Common and Rare 
Causes of 
Hyperammonemia?
ARTEFACTUAL INCREASE?
- Poor specimen quality 
- Difficult venipuncture  
- Hemolysis?
- Skin contamination?
- Contaminated tube?
- Delayed analysis?
- Transient Hyperammonemia ?
ACQUIRED?
-Liver Failure or Impairment  
-Urinary Tract Infection  
-GI Bacterial overgrowth  
-Drugs; e.g. valproate, chemotherapy 
-Total parenteral nutrition  
-Sick Baby: e.g. asphyxia, sepsis, Reyes 
Syndrome?
UREA CYCLE DISORDERS?
Inherited Deficiencies of: ?
- N-Acetyl Glutamate Synthase (NAGS) ?
- Carbamoyl Phosphate Synthase (CPS) ?
- Ornithine Transcarbamylase (OTC) ?
- Argininosuccinate Synthase (Citrullinaemia) ?
- Argininosuccinate Lyase ?
(Argininosuccinic Aciduria) ?
- Arginase (Argininaemia)   
- Citrin Deficiency ?
OTHER METABOLIC DISORDERS?
- Organic Acidurias ?
- Disorders of Fatty Acid Oxidation?
- HHH Syndrome?
- Lysinuric Protein Intolerance?
- Hyperinsulinaemic Hyerammonaemia?
- Ornithine Aminotransferase Deficiency?
- Respiratory Chain       Defects?
- Pyruvate Dehydrogenase Deficiency?
- Congenital lactic acidosis?
Hyperammonemia is a metabolic disturbance characterised by an excess levels of ammonia in the blood. 
Ammonia is a highly potent neurotoxin well known for its implication in hepatic encephalopathy.
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???????????? ????????????????????????????? ???
28th Feb 2018: Morning of a CME Seminar when the  Technologists and Faculty in Biochemical Genetics Laboratory  AKU  
???????????????????????????????????????? ?????????????????????????????????????????????????????????????????????????????
28th Feb 2017: CME Seminar on World Rare Disease Day at Aga Khan University.
28th Feb 2016: CME Seminar at AKU on Inherited Metabolic Disorders to mark World Rare Disease Day
hospitals.aku.edu/Karachi/clinical-laboratories
